Purpose Peripheral neuropathy (PN) is a common and distressing complication from
chemotherapy. Symptoms often, but not always, improve with time. The prevalence of long …

Background Many of the 3.8 million breast cancer survivors in the United States experience
long‐term side effects of cancer therapy including peripheral neuropathy (PN). We assessed …

Background In the current study, the authors investigated the incidence of moderate to
severe chemotherapy‐induced peripheral neuropathy (CIPN) for chemotherapy regimens …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with
chemotherapy, but researchers rarely study its risk factors, fall risk, and prevalence in long …

Neuropathic pain (NP) remains difficult to control for a significant number of patients with
cancer. Chemotherapy-induced peripheral neuropathy (CIPN) has been postulated as an …

Background The prevalence of persistent peripheral neuropathy (PN) in early-stage breast
cancer (ESBC) survivors is largely unknown. We explored the occurrence and risk factors of …

Purpose To describe the prevalence, severity, and risk factors of chemotherapy-induced
peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among …

Breast cancer is the most common cancer among women worldwide, and survival rates are
increasing. Chemotherapy-associated peripheral neuropathy (PN) is clinically important …

Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting
side effect of taxane and platinum chemotherapy for breast cancer. Clinicians cannot …

Background The long-term effects of chemotherapy are sparsely reported. Peripheral
neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the …